Jessica Bond, MA, LPC, SAC, ACS Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 20 Northview Ter, Cedar Grove, NJ 07009 Phone: 201-701-1391 |
Doris M. Dinallo, RN, LCADC, LPC, BCPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 1425 Pompton Ave Fl 2, Cedar Grove, NJ 07009 Phone: 973-997-9201 |
Gabrielle Sanroman, LAC, NCC Counselor Medicare: Not Enrolled in Medicare Practice Location: 19 Lakewood Ave, Cedar Grove, NJ 07009 Phone: 862-596-5218 |
Sheryl M Larner, EDD Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 882a1 Pompton Ave, Cedar Grove, NJ 07009 Phone: 973-239-0852 |
Danielle Helder, LPC, LCADC Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 147 Tierney Dr, Cedar Grove, NJ 07009 Phone: 201-737-8920 |
Ms. Sofia Macias, LPC, LCADC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 91 Pompton Ave, Cedar Grove, NJ 07009 Phone: 973-370-4343 |
Miss Saskia Lily Pownall-gray, MSW Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 99 E Lindsley Rd, Cedar Grove, NJ 07009 Phone: 347-414-1769 |
Howard Marc Schulman Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 1425 Pompton Ave Apt 3, Cedar Grove, NJ 07009 Phone: 201-658-1280 |
Mrs. Lisa Marie Cassilli, LPC, NCC, SAC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 12 Dogwood Ct, Cedar Grove, NJ 07009 Phone: 973-868-8554 |
Dr. Ronald Wei, MD Counselor - Mental Health Medicare: Medicare Enrolled Practice Location: 204 Grove Ave, Cedar Grove, NJ 07009 Phone: 973-571-2833 |
Nicole Sylvestro Counselor Medicare: Not Enrolled in Medicare Practice Location: 4 Reservoir Pl, Cedar Grove, NJ 07009 Phone: 973-851-5662 |
Dr. Michael Patrick Filiaci, PH.D. Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 908 Pompton Ave Ste B2, Cedar Grove, NJ 07009 Phone: 862-277-0198 |
Mr. Steven Scrivo Jr., L.P.C. Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 145 Ridge Rd Apt B, Cedar Grove, NJ 07009 Phone: 973-941-7312 |
Jayme Ganey, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 392 Fairview Ave, Cedar Grove, NJ 07009 Phone: 973-804-9745 |
News Archive
Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free survival compared with docetaxel alone.
Test system on Drosophila should provide the key to histone function. The genetic inherited material DNA was long viewed as the sole bearer of hereditary information. The function of its packaging proteins, the histones, was believed to be exclusively structural. Additional genetic information can be stored, however, and passed on to subsequent generations through chemical changes in the DNA or histones. Scientists from the Max Planck Institute for Biophysical Chemistry in Göttingen have succeeded in creating an experimental system for testing the function of such chemical histone modifications and their influence on the organism.
In a first of its kind clinical trial, Debra Zand, Ph.D., and her team at Saint Louis University, will run an intervention program to help parents address and manage their children's challenging behaviors immediately after being diagnosed with autism.
A tiny, translucent juvenile zebrafish, on the hunt for even littler prey, has offered up a big insight into how a specific circuit of nerve cells functions in the brain. The technique used to illuminate this circuitry, and the fish model itself, provide one of the first insights into the way individual sets of neurons control a specific behavior.
IntelGenx Corp. (TSX VENTURE:IGX)(OTCBB:IGXT) ("IntelGenx") previously announced that the New Drug Application (NDA) filing for the antidepressant CPI-300, which it developed with Cary Pharmaceuticals ("Cary Pharma") had been accepted by the U.S. Food and Drug Administration (FDA) for standard review. CPI-300 is a novel, high strength of Bupropion HCl, the active ingredient in Wellbutrin XL®.
› Verified 1 days ago